scholarly journals Cardioprotection by direct factor Xa inhibition in angiotensin II overexpression

Author(s):  
Masaki Mogi
2018 ◽  
Vol 118 (09) ◽  
pp. 1528-1534 ◽  
Author(s):  
Uwe Zeymer ◽  
Benedikt Schrage ◽  
Dirk Westermann

AbstractThe optimal anti-thrombotic therapy for secondary prevention after an acute coronary syndrome is still a matter of debate. While current guidelines recommend dual anti-platelet therapy with aspirin and a P2Y12 inhibitor over 12 months especially in patients with stent implantation, the value of prolonged anticoagulation is still controversial. In the ATLAS-TIMI 52 trial, a low-dose direct factor Xa inhibition with rivaroxaban compared with placebo reduced the combined primary endpoint of cardiovascular mortality, myocardial infraction and stroke with an increase in major bleeding complications. This article discusses the value and problems of adding low-dose rivaroxaban to anti-platelet therapy as secondary prevention measure after an acute myocardial infarction. It will describe the pros and cons of intensified anti-platelet therapy versus dual pathway inhibition and give recommendations for different patient groups in clinical practice.


Circulation ◽  
2002 ◽  
Vol 105 (20) ◽  
pp. 2385-2391 ◽  
Author(s):  
Christopher K. Dyke ◽  
Richard C. Becker ◽  
Neal S. Kleiman ◽  
Judith S. Hochman ◽  
Edwin G. Bovill ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document